The Global anaphylaxis treatment market was valued at US$ 4,878.89 Mn and expected to grow at 8.9% Compound Annual Growth Rate (CAGR) over the 2021-2027. Anaphylaxis is a serious, allergic reaction that is to be treated immediately. Anaphylaxis is a life-threatening reaction with cardiovascular, respiratory, gastrointestinal, or cutaneous manifestations resulting from exposure to an offending agent, usually insect sting, food, physical factor, or medication. It is typical causes more than one of the symptoms such as throat or tongue swelling, itchy rash, vomiting, shortness of breath, light-headedness, and low blood pressure. Anaphylaxis occurs due to the release of mediators from white blood cells that initiate immunological or non immunologic mechanisms. Anaphylaxis is primarily treated by epinephrine through IV route or intra-muscular route. Addition to epinephrine, antihistamines, H2 blockers, vasodilators, and steroids are used to relieve the symptoms. Global Anaphylaxis treatment market is much consolidated in nature due to the presence of very few players in the market. The introduction of the auto-injectors to treat the anaphylaxis revolutionised the anaphylaxis treatment market. Market players are increasing their market presence by collaborations and partnerships. In addition, marketers focusing on the product launches and expanding into other regions for better revenue realization. For instance, in 2015, ALK-Abelló and bioCSL (CSL Limited) entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX in Europe and GRASTEK in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bio CLS will undertake registration and commercialisation of the products. Companies reducing the costs by introducing the generic, cheaper versions of the epinephrine auto-injectors to penetrate into the market. For instance, Mylan N.V. has introduced the generic version of EpiPen at half the price. The initial pack of two was sold at US$600 until December 2016 which will be sold at US$ 300 from January 2017.